109 related articles for article (PubMed ID: 1374195)
21. Fibrinolytic activity and protein C in preeclampsia.
Aznar J; Gilabert J; Estellés A; España F
Thromb Haemost; 1986 Jun; 55(3):314-7. PubMed ID: 3092388
[TBL] [Abstract][Full Text] [Related]
22. Fibrinolytic changes and the influence of the early perfusate in orthotopic liver transplantation with intraoperative aprotinin treatment.
Himmelreich G; Kierzek B; Neuhaus P; Slamer KJ; Riess H
Transplant Proc; 1991 Jun; 23(3):1936-7. PubMed ID: 1712137
[No Abstract] [Full Text] [Related]
23. Plasminogen activation system of the platelets.
Park S
Rinsho Byori; 1992 Mar; Suppl 92():131-43. PubMed ID: 1583771
[No Abstract] [Full Text] [Related]
24. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states.
Kruithof EK; Gudinchet A; Bachmann F
Thromb Haemost; 1988 Feb; 59(1):7-12. PubMed ID: 3129809
[TBL] [Abstract][Full Text] [Related]
25. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
Costantini V; Zacharski LR; Memoli VA; Kudryk BJ; Rousseau SM; Stump DC
Cancer Res; 1991 Jan; 51(1):354-8. PubMed ID: 1846311
[TBL] [Abstract][Full Text] [Related]
26. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
27. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
[TBL] [Abstract][Full Text] [Related]
28. Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis.
Aya N; Yoshioka K; Murakami K; Hino S; Okada K; Matsuo O; Maki S
J Pathol; 1992 Mar; 166(3):289-95. PubMed ID: 1381427
[TBL] [Abstract][Full Text] [Related]
29. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of the inhibition by plasminogen activator inhibitor 2 of urokinase isolated from human urine and recombinant microorganisms. Further evidence for correct tertiary structure of recombinant urokinase.
Cramer J; Steffens G; Günzler WA; Hess V; Flohé L
Arzneimittelforschung; 1988 Aug; 38(8):1196-8. PubMed ID: 3143371
[TBL] [Abstract][Full Text] [Related]
31. Fibrinolytic system of cultured endothelial cells: regulation by plasminogen activator inhibitor.
Loskutoff DJ; Ny T; Sawdey M; Lawrence D
J Cell Biochem; 1986; 32(4):273-80. PubMed ID: 3100541
[TBL] [Abstract][Full Text] [Related]
32. Advances in clinical fibrinolysis.
Hessel LW; Kluft C
Clin Haematol; 1986 May; 15(2):443-63. PubMed ID: 2942332
[TBL] [Abstract][Full Text] [Related]
33. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.
Bruckner A; Filderman AE; Kirchheimer JC; Binder BR; Remold HG
Cancer Res; 1992 Jun; 52(11):3043-7. PubMed ID: 1375533
[TBL] [Abstract][Full Text] [Related]
34. [Lipoprotein-mediated functional changes in the fibrinolytic system in the genesis of atherosclerosis].
García Frade LJ; García Avello A
Sangre (Barc); 1991 Feb; 36(1):25-8. PubMed ID: 1649496
[No Abstract] [Full Text] [Related]
35. Purification of a plasminogen activator inhibitor indistinguishable from alpha1-antitrypsin and an urokinase inhibitor in pregnancy plasma.
Clemmensen I; Thorsen S; Müllertz S
Haemostasis; 1976; 5(4):218-30. PubMed ID: 826461
[TBL] [Abstract][Full Text] [Related]
36. Natural inhibitors of fibrinolysis.
Juhan-Vague I; Aillaud MF; Serradimigni A
Haemostasis; 1986; 16 Suppl 3():16-20. PubMed ID: 3095194
[No Abstract] [Full Text] [Related]
37. Inhibition of tissue plasminogen activators and urokinase by human saliva.
Haze C; Garfunkel AA; Eldor A; Kadouri A
Oral Surg Oral Med Oral Pathol; 1994 Apr; 77(4):356-61. PubMed ID: 8015799
[TBL] [Abstract][Full Text] [Related]
38. [Tissue-type plasminogen activator and plasminogen activator inhibitor].
Sakata Y
Nihon Rinsho; 1989 Apr; 47(4):752-8. PubMed ID: 2501537
[No Abstract] [Full Text] [Related]
39. Possibilities of intervention in intrinsic and extrinsic lysis programs.
Lowe GD
Ann N Y Acad Sci; 1992 Dec; 667():272-7. PubMed ID: 1309044
[No Abstract] [Full Text] [Related]
40. [Fibrinolytic tests and the related factors].
Matsuda T
Nihon Naika Gakkai Zasshi; 1991 Jun; 80(6):834-8. PubMed ID: 1919196
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
